Download PDF
Thromb Haemost 1987; 57(03): 314-321
DOI: 10.1055/s-0038-1651124
Original Article
Schattauer GmbH Stuttgart

The Development and Characterisation of Antibodies to Human Factor VIII in Haemophilic Dogs

Janet D Littlewood
*   The Department of Clinical Veterinary Medicine, University of Cambridge, London, UK
,
T W Barrowcliffe
+   The National Institute for Biological Standards and Control, London, UK
› Author Affiliations
Further Information

Publication History

Received 02 December 1986

Accepted after revision 23 February 1987

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Four haemophilic dogs received infusions of human factor VIII concentrates, and developed inhibitors to human F VIII. These inhibitors cross-reacted with canine F VIII with parallel increases and decreases in titre. Cross-reaction was also found to porcine F VIII but changes in titre did not correlate with anti-human and anti-canine titres. These inhibitors were found to be immunoglobulins, and antibodies were detected against other proteins found in concentrates. Kinetic studies showed that in all four dogs the F VIII inhibitors were Type II antibodies. One of the dogs behaved as a “high-responder”, whilst another was more analogous to a “low-responder” patient. Phospholipid protection experiments in vitro demonstrated that some antibodies could be prevented from inhibiting F VIII, and porcine F VIII was particularly well protected against inhibition.

Keywords

Haemophilia A - Dogs - Factor VIII concentrates - Phospholipids - Factor VIII inhibitors - Factor VIII antibodies
 

  • References

  • 1 Shapiro SS. Antibodies to blood coagulation factors. Clinics in Haematology 1979; 8: 207-214
    PubMedGoogle Scholar
  • 2 Roberts HR. Hemophilics with inhibitors: therapeutic options. N Engl J Med 1981; 305: 757-758
    CrossrefPubMedGoogle Scholar
  • 3 Aronson DL. Conjectures on factor VIII bypassing activity. Prog Clin Biol Res 1981; 72: 103-121
    PubMedGoogle Scholar
  • 4 Barrowcliffe TW, Kemball-Cook G, Gray E. Factor VIII inhibitor by-passing activity: a suggested mechanism of action. Thromb Res 1981; 21: 181-186
    CrossrefPubMedGoogle Scholar
  • 5 Barrowcliffe TW, Kemball-Cook G, Gray E. Binding to phospholipid protects factor VIII from inactivation by human antibodies. J Lab Clin Med 1983; 101: 34-43
    PubMedGoogle Scholar
  • 6 Muntean W. Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma. Wiener Klinische Wochenschrift 1984; 96: 829-832
    PubMedGoogle Scholar
  • 7 Barrowcliffe TW, Kemball-Cook G, Gray E. Overcoming factor VIII inhibitors: a possible new approach. Scand J Haematol (Suppl. 40) 1984; 33: 207-212
    PubMedGoogle Scholar
  • 8 Barrowcliffe TW, Kemball-Cook G, Gray E. Effect of phospholipid on factor VIII inactivation. Prog Clin Biol Res 1984; 150: 251-263
    PubMedGoogle Scholar
  • 9 Barrowcliffe TW, Stocks J, Gray E. Preparation of a stable phospholipid reagent for coagulation assays. Haemostas 1982; 11: 96-101
    PubMedGoogle Scholar
  • 10 Giles AR, Tinlin S, Greenwood P, Hoogendorn H, Greenwood R. Canine model of haemophilia with antibodies to factor VIII: C. Thromb Haemostas 1983; 50: 344 (Abstr.)
    PubMedGoogle Scholar
  • 11 Giles AR, Tinlin S, Hoogendorn H, Greenwood P, Greenwood R. Development of factor VIII: C antibodies in dogs with hemophilia A (factor VIII deficiency). Blood 1984; 63: 451-456
    PubMedGoogle Scholar
  • 12 Pijnappels M IM, Briet E, van der Zweet GTh, Huisden R, van Tilburg NH, Eulderink F. Evaluation of the cuticle bleeding time in canine haemophilia A. Thromb Haemostas 1986; 55: 70-73
    PubMedGoogle Scholar
  • 13 Kasper CK, Aledort LM, Counts RB, Edson JR, Frantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872
    PubMedGoogle Scholar
  • 14 Biggs R, Austen D EG, Denson K WE, Rizza CR, Borrett R. The mode of action of antibodies which destroy factor VIII: antibodies which have second-order concentration graphs. Br J Haematol 1972; 23: 125-135
    CrossrefPubMedGoogle Scholar
  • 15 Ghosh S, Rizza CR. Changes in the character of factor VIII inhibitors following factor VIII transfusion. Scand J Haematol 1984; 33: 239-243
    PubMedGoogle Scholar
  • 16 Porath J, Axén R, Ernback S. Chemical coupling of proteins to agarose. Nature 1967; 215: 1491-1492
    CrossrefPubMedGoogle Scholar
  • 17 Biggs R, Austen D EG, Denson K WE, Borrett R, Rizza CR. Mode of action of antibodies which destroy factor VIII: antibodies which give complex concentration graphs. Br J Haematol 1972; 23: 137-155
    CrossrefPubMedGoogle Scholar
  • 18 Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982; 60: 1103-1109
    CrossrefPubMedGoogle Scholar
  • 19 Kemball-Cook G, Barrowcliffe TW. Factor VIII concentrates contain factor VIII procoagulant antigen bound to phospholipid. Br J Haematol 1986; 63: 425-434
    CrossrefPubMedGoogle Scholar
  • 20 Hill F GH, Enayat MS. Multimeric analysis of eight lyophilized Factor VIII concentrates. Br J Haematol 1985; 60: 201-203
    CrossrefPubMedGoogle Scholar
  • 21 Little wood JD, Kemball-Cook G, White R AS, Barrowcliffe TW. Factor VIII-phospholipid infusions in haemophilic dogs. La Ricerca 1986; 16: 103
    PubMedGoogle Scholar